Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
32,826,058
-
Shares change
-
+1,223,758
-
Total reported value, excl. options
-
$801,283,858
-
Value change
-
+$19,636,706
-
Put/Call ratio
-
29.15%
-
Number of buys
-
33
-
Number of sells
-
-24
-
Price
-
$24.41
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q1 2021
72 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q1 2021.
ADC Therapeutics SA - Common Shares (ADCT) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32,826,058 shares
of 124,058,172 outstanding shares and own 26.46% of the company stock.
Largest 10 shareholders include FMR LLC (7,761,585 shares), Redmile Group, LLC (7,308,418 shares), JPMORGAN CHASE & CO (3,142,253 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,745,794 shares), ALLIANCEBERNSTEIN L.P. (2,630,491 shares), Vantage Consulting Group Inc (1,680,149 shares), Grosvenor Holdings, L.L.C. (1,517,212 shares), BAKER BROS. ADVISORS LP (1,418,107 shares), EVENTIDE ASSET MANAGEMENT, LLC (914,739 shares), and MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC (607,800 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.